Centanafadine Hydrochloride

DRUG2 trials

Sponsors

Otsuka Pharmaceutical Development & Commercialization, Inc.

Conditions

Attention Deficit/Hyperactivity DisorderAttention-Deficit/Hyperactivity Disorder

Phase 3

A Trial of Centanafadine Efficacy and Safety in Adolescents With Attention- Deficit/Hyperactivity Disorder

CompletedNCT05257265

Otsuka Pharmaceutical Development & Commercialization, Inc.Attention-Deficit/Hyperactivity Disorder

Start: 2022-02-02End: 2023-10-05Updated: 2024-09-27

A Trial of Centanafadine Long-term Safety in Children and Adolescents With Attention-deficit/Hyperactivity Disorder.

CompletedNCT05279313

Otsuka Pharmaceutical Development & Commercialization, Inc.Attention Deficit/Hyperactivity Disorder

Start: 2022-02-24End: 2026-04-24Updated: 2026-05-14

Related Papers

Efficacy of Centanafadine for Executive Functioning and Learning Problems in Children and Adolescents with Attention-Deficit/Hyperactivity Disorder.

2026-04-09

Centanafadine for Attention-Deficit/Hyperactivity Disorder in Adolescents: A Randomized Clinical Trial

Journal of the American Academy of Child & Adolescent Psychiatry2025-07-013 citations